Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
15/09/2025
Bank of Thailand: Will implement measures to reduce the impact of gold trading on the Thai baht.
Latest
1 m ago
Longpan Technology (603906.SH), a holding subsidiary, signed a purchase cooperation agreement for lithium iron phosphate cathode materials with Ningde Times.
1 m ago
Strong stock tracking: Main funds have continuously flowed into 47 stocks for 5 consecutive days.
3 m ago
On September 15, local time, Swiss pharmaceutical giant Novartis signed a licensing agreement with biotechnology company Monte Rosa worth up to $5.7 billion for the development of drugs to treat immune-mediated diseases. According to the agreement, Monte Rosa will receive a prepayment of $120 million. The company's stock price surged 50% in premarket trading.
3 m ago
Novartis reaches a $57 billion licensing deal.
3 m ago
From Bayer's confirmation to the signing of an agreement by the company to sell 60% of its stake in the Sino-American Shanghai Pharmaceuticals Co., Ltd., Bayer has reaffirmed its strong commitment to the Chinese market and will continue to invest in the market under the "China 2030 Strategy." In the future, Bayer will continue to accelerate the introduction of innovative therapies in a wide range of disease areas and fully enhance drug accessibility. (Yi Cai)
See all latest